I don't think they have told us the full story (and why would they help their competitors and suppliers gain a possible advantage), but I certainly salute the CEO for getting on the front foot. That is quite a surprise for next year. Their blood centre margins are impacted, and they are expecting recovery medium term. Is that CFO speak for not predicting recovery at all, but hoping for the best. (Ms Linton) "anticipated that returning to pre-COVID gross margins in the division could be achieved “in the medium term”" (quoting afr).
Not easy for CSL to stay at the forefront of relevant IP to keep managing costs. Suppliers can also price radically just as easily as CSL can it seems.
When will we be finally moving across to cell cultured blood products? So much work to keep things safe with a human supply. CSL and competitors do a great job all the same.
Ann: Market Update, page-33
Add CSL (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$311.70 |
Change
0.580(0.19%) |
Mkt cap ! $150.6B | |||
| Open | High | Low | Value | Volume |
| $308.37 | $311.70 | $307.33 | $411.6M | 1.374M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 55 | $310.93 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $311.74 | 904 | 1 |
View Market Depth
| Last trade - 16.10pm 19/07/2024 (20 minute delay) ? |
| CSL (ASX) Chart |